Publications database

Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate is increasing on the legalisation...

The use of substitution drugs for the treatment of opioid dependence represents a key evidence-based response to heroin problems in Europe. However, the diversion of these medicines from their intended use in...

Psychosocial interventions are structured psychological or social interventions used to address substance-related problems. They can be used at different stages of drug treatment to identify the problem, treat it and assist with...

A journalists’ guide to upcoming events and products from the EU drugs agency in Lisbon, May 2016.

This report explores the recent resurgence in use of MDMA in Europe and increased availability of high-strength MDMA tablets, crystals and powders. It notes that the picture is not uniform across European...

April–June 2016​ In this issue: 2016 EU Drug Markets Report | Monitoring illicit drugs in wastewater | UNGASS 2016 | Strengthening early warning on new synthetic opioids | New EMCDDA products and...

The EU Drug Markets Report 2016 is the second comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis provided in this report spans numerous...

This report includes estimates of the total size of the retail drug market in the European Union (EU) in 2013 for cannabis, heroin, cocaine, amphetamines and ecstasy. October 2018: An error has...

The EMCDDA strategy and work programme for 2016–18 and the 2016 annual work programme is based on the EMCDDA’s vision to contribute to a more secure and a healthier Europe. A more...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...